S&P 500   5,086.86 (-0.04%)
DOW   39,152.59 (+0.05%)
QQQ   437.63 (+0.19%)
AAPL   181.71 (-0.44%)
MSFT   409.64 (-0.17%)
META   483.14 (-0.18%)
GOOGL   140.09 (-2.69%)
AMZN   175.78 (+0.45%)
TSLA   197.49 (+2.88%)
NVDA   797.31 (+1.16%)
NIO   5.65 (+4.63%)
AMD   176.35 (-0.10%)
BABA   76.32 (+0.47%)
T   16.62 (-1.07%)
F   12.15 (+0.08%)
MU   90.17 (+4.85%)
CGC   3.47 (+3.27%)
GE   154.64 (+0.85%)
DIS   108.36 (+0.58%)
AMC   4.53 (+2.03%)
PFE   27.22 (-1.95%)
PYPL   59.79 (+1.06%)
XOM   104.63 (+0.76%)
S&P 500   5,086.86 (-0.04%)
DOW   39,152.59 (+0.05%)
QQQ   437.63 (+0.19%)
AAPL   181.71 (-0.44%)
MSFT   409.64 (-0.17%)
META   483.14 (-0.18%)
GOOGL   140.09 (-2.69%)
AMZN   175.78 (+0.45%)
TSLA   197.49 (+2.88%)
NVDA   797.31 (+1.16%)
NIO   5.65 (+4.63%)
AMD   176.35 (-0.10%)
BABA   76.32 (+0.47%)
T   16.62 (-1.07%)
F   12.15 (+0.08%)
MU   90.17 (+4.85%)
CGC   3.47 (+3.27%)
GE   154.64 (+0.85%)
DIS   108.36 (+0.58%)
AMC   4.53 (+2.03%)
PFE   27.22 (-1.95%)
PYPL   59.79 (+1.06%)
XOM   104.63 (+0.76%)
S&P 500   5,086.86 (-0.04%)
DOW   39,152.59 (+0.05%)
QQQ   437.63 (+0.19%)
AAPL   181.71 (-0.44%)
MSFT   409.64 (-0.17%)
META   483.14 (-0.18%)
GOOGL   140.09 (-2.69%)
AMZN   175.78 (+0.45%)
TSLA   197.49 (+2.88%)
NVDA   797.31 (+1.16%)
NIO   5.65 (+4.63%)
AMD   176.35 (-0.10%)
BABA   76.32 (+0.47%)
T   16.62 (-1.07%)
F   12.15 (+0.08%)
MU   90.17 (+4.85%)
CGC   3.47 (+3.27%)
GE   154.64 (+0.85%)
DIS   108.36 (+0.58%)
AMC   4.53 (+2.03%)
PFE   27.22 (-1.95%)
PYPL   59.79 (+1.06%)
XOM   104.63 (+0.76%)
S&P 500   5,086.86 (-0.04%)
DOW   39,152.59 (+0.05%)
QQQ   437.63 (+0.19%)
AAPL   181.71 (-0.44%)
MSFT   409.64 (-0.17%)
META   483.14 (-0.18%)
GOOGL   140.09 (-2.69%)
AMZN   175.78 (+0.45%)
TSLA   197.49 (+2.88%)
NVDA   797.31 (+1.16%)
NIO   5.65 (+4.63%)
AMD   176.35 (-0.10%)
BABA   76.32 (+0.47%)
T   16.62 (-1.07%)
F   12.15 (+0.08%)
MU   90.17 (+4.85%)
CGC   3.47 (+3.27%)
GE   154.64 (+0.85%)
DIS   108.36 (+0.58%)
AMC   4.53 (+2.03%)
PFE   27.22 (-1.95%)
PYPL   59.79 (+1.06%)
XOM   104.63 (+0.76%)
NASDAQ:INM

InMed Pharmaceuticals (INM) Stock Price, News & Analysis

$0.43
+0.02 (+4.52%)
(As of 10:25 AM ET)
Today's Range
$0.40
$0.43
50-Day Range
$0.32
$0.42
52-Week Range
$0.29
$2.08
Volume
110,815 shs
Average Volume
128,427 shs
Market Capitalization
$2.58 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

InMed Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.66% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.67mentions of InMed Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$29,601 Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.15 out of 5 stars


INM stock logo

About InMed Pharmaceuticals Stock (NASDAQ:INM)

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

INM Stock Price History

INM Stock News Headlines

InMed Pharmaceuticals Welcomes New CFO Neeta Jagpal
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
InMed Announces Results of 2023 Annual General Meeting
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
InMed Pharmaceuticals Inc INM
Why Is InMed Pharmaceuticals (INM) Stock Down 25% Today?
INM - InMed Pharmaceuticals Inc.
See More Headlines
Receive INM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for InMed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
2/26/2024
Next Earnings (Estimated)
5/20/2024
Fiscal Year End
6/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:INM
Fax
N/A
Employees
13
Year Founded
N/A

Profitability

Net Income
$-7,950,000.00
Net Margins
-115.76%
Pretax Margin
-115.71%

Debt

Sales & Book Value

Annual Sales
$4.14 million
Book Value
$3.63 per share

Miscellaneous

Free Float
5,973,000
Market Cap
$2.55 million
Optionable
Not Optionable
Beta
-0.02
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Mr. Eric A. Adams B.S. Chem. (Age 61)
    M.I.B., President, CEO & Director
    Comp: $347.82k
  • Mr. Michael Woudenberg P.Eng. (Age 55)
    Chief Operating Officer
    Comp: $287.54k
  • Ms. Alexandra Diane-Janet Mancini M.Sc. (Age 71)
    Senior Vice President of Clinical & Regulatory Affairs
    Comp: $279.39k
  • Dr. Sazzad Hossain M.Sc. (Age 66)
    Ph.D., Co-Founder
    Comp: $135.96k
  • Mr. Jonathan R. Tegge (Age 34)
    Interim Chief Financial Officer
  • Ms. Sarah Li CPA
    CGA, VP of Accounting & Controller
  • Colin Clancy
    Senior Director of Investor Relations
  • Mr. Jerry P. Griffin
    Vice President of Sales & Marketing
  • Dr. Eric Chih-Hsien Hsu (Age 54)
    Senior Vice President of Preclinical Research & Development
    Comp: $253.46k
  • Dr. Shane A. Johnson Ph.D.
    Senior VP & GM of BayMedica














INM Stock Analysis - Frequently Asked Questions

How have INM shares performed in 2024?

InMed Pharmaceuticals' stock was trading at $0.4160 at the start of the year. Since then, INM shares have increased by 1.0% and is now trading at $0.42.
View the best growth stocks for 2024 here
.

Are investors shorting InMed Pharmaceuticals?

InMed Pharmaceuticals saw a drop in short interest in January. As of January 31st, there was short interest totaling 40,100 shares, a drop of 43.4% from the January 15th total of 70,800 shares. Based on an average daily trading volume, of 198,000 shares, the days-to-cover ratio is currently 0.2 days.
View InMed Pharmaceuticals' Short Interest
.

When is InMed Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our INM earnings forecast
.

How were InMed Pharmaceuticals' earnings last quarter?

InMed Pharmaceuticals Inc. (NASDAQ:INM) released its quarterly earnings data on Wednesday, November, 10th. The company reported ($6.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($8.75) by $2.50. InMed Pharmaceuticals had a negative net margin of 115.76% and a negative trailing twelve-month return on equity of 54.31%.

When did InMed Pharmaceuticals' stock split?

InMed Pharmaceuticals's stock reverse split on Wednesday, September 7th 2022. The 1-25 reverse split was announced on Wednesday, September 7th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, September 7th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Who are InMed Pharmaceuticals' major shareholders?

InMed Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Armistice Capital LLC (3.92%). Insiders that own company stock include Andrew Hull, Bruce Colwill, Eric A Adams and Shane Aaron Johnson.
View institutional ownership trends
.

How do I buy shares of InMed Pharmaceuticals?

Shares of INM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:INM) was last updated on 2/26/2024 by MarketBeat.com Staff